US Stock MarketDetailed Quotes
NNVC Nanoviricides
- 2.240
- +0.040+1.82%
Close Jul 26 16:00 ET
- 2.300
- +0.060+2.68%
Post 18:32 ET
26.46MMarket Cap-2731P/E (TTM)
2.350High2.160Low162.13KVolume2.170Open2.200Pre Close364.95KTurnover1.44%Turnover RatioLossP/E (Static)11.81MShares3.59052wk High2.48P/B25.24MFloat Cap1.00052wk Low--Dividend TTM11.27MShs Float262.500Historical High--Div YieldTTM8.63%Amplitude1.000Historical Low2.250Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Nanoviricides Stock Forum
$Dow Jones Industrial Average(.DJI.US)$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index(.SPX.US)$ fell by 1.39%, and the $Nasdaq Composite Index(.IXIC.US)$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth(UNH.US)$, $Johnson & Johnson(JNJ.US)$, and $Cisco(CSCO.US)$ l...
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
NanoViricides discusses its development of NV-387, a drug targeting multiple respiratory viruses including COVID, RSV, Influenza, and Bird Flu.
NV-387 has shown superior activity in animal models compared to approved drugs and has completed Phase I trials with no adverse events.
The company is planning Phase II tri...
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, a leader in antiviral nanomedicines, presents the progress of its drug candidate NV-387, which has completed Phase I clinical trials with no adverse events reported. NV-387 has demonstrated significant efficacy against various viruses, including RSV, Influenza, ...
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides announced a significant advancement in its lead antiviral agent, NV-387. This drug, designed for broad-spectrum antiviral treatment, has shown prolonged blood concentration levels in non-human primate models, indicating the potential for infrequent dosing. NV-387's unique polymeric design helps sustain drug levels, making it effecti...
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, T...
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
No comment yet